Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York ...

Like Novo Nordisk and Lilly, Metsera has been set up to develop a pipeline of weight-loss therapies based on GLP-1 receptor agonism, with a focus on peptides and peptide-antibody conjugates.

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, bad news for Pfizer's (PFE) danuglipron and uncertainty about whether ...

Pfizer to discontinue danuglipron weight-loss drug, but has other obesity treatments ... "second-most advanced" oral GLP-1 in development. Metsera Inc. also stands to benefit, as while its oral ...

“2024 was a year of exceptional execution and acceleration at Metsera (MTSR),” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from first-in ...